This Article Full Text Full Text (PDF) All Versions of this Article: 36/11/2500    most recent 01.STR.0000185699.37843.14v1 Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Demaerschalk, B. M. Articles by Yip, T. R. Search for Related Content PubMed PubMed Citation Articles by Demaerschalk, B. M. Articles by Yip, T. R. Pubmed/NCBI databases Substance via MeSH Medline Plus Health Information Stroke Related Collections Acute Cerebral Infarction Emergency treatment of Stroke Thrombolysis

(Stroke. 2005;36:2500.)
© 2005 American Heart Association, Inc.

Research Reports

Economic Benefit of Increasing Utilization of Intravenous Tissue Plasminogen Activator for Acute Ischemic Stroke in the United States

From the Department of Neurology (B.M.D.), Mayo Clinic College of Medicine, Mayo Clinic Arizona, Scottsdale, Ariz; and the Department of Physical Medicine and Rehabilitation (T.R.Y.), University of Saskatchewan, Saskatoon, Saskatchewan, Canada.

Correspondence to Bart M. Demaerschalk, MD, MSc, FRCPC, Department of Neurology, Mayo Clinic College of Medicine, Mayo Clinic Arizona, 13400 E Shea Blvd, Scottsdale, AZ 85259. E-mail Demaerschalk.bart{at}mayo.edu

Background and Purpose— Health economic analyses of intravenous tissue plasminogen activator (tPA) in acute ischemic stroke reveal a substantial cost savings. Unfortunately, tPA is vastly underused. The purpose of this study was to determine the economic impact of increasing tPA utilization in the United States.

Methods— Annual incidence estimates of ischemic stroke in the United States and individual states were obtained. The proportion of all ischemic stroke patients who receive tPA was derived from published data. Economic analyses that report the expected annual cost savings of tPA were consulted. The analysis was conducted from the perspective of the healthcare system over a time period of 1 year. With incremental increases in the proportion of all ischemic stroke patients treated with tPA, potential cost savings were recalculated. The outcomes are expressed in dollars saved annually.

Results— There are 616 000 new ischemic stroke patients annually. A $600 net cost savings is associated with each tPA-treated patient. Currently, an estimated 2% of all ischemic stroke patients receive tPA. If the proportion was increased to 4, 6, 8, 10, 15, or 20%, the realized cost savings would be approximately $15, 22, 30, 37, 55, and 74 million, respectively.

Conclusions— If even small manageable increases in the proportion of all ischemic stroke patients who received tPA were achieved, it would result in an enormous realized savings for America’s healthcare system.

Key Words: acute stroke • economics • TPA

This article has been cited by other articles:

				L. H. Schwamm, H. J. Audebert, P. Amarenco, N. R. Chumbler, M. R. Frankel, M. G. George, P. B. Gorelick, K. B. Horton, M. Kaste, D. T. Lackland, et al. Recommendations for the Implementation of Telemedicine Within Stroke Systems of Care: A Policy Statement From the American Heart Association Stroke, July 1, 2009; 40(7): 2635 - 2660. [Full Text] [PDF]

				R. Luengo-Fernandez, A. M. Gray, and P. M. Rothwell Costs of Stroke Using Patient-Level Data: A Critical Review of the Literature Stroke, February 1, 2009; 40(2): e18 - e23. [Abstract] [Full Text] [PDF]

				G. W. Albers, P. Amarenco, J. D. Easton, R. L. Sacco, and P. Teal Antithrombotic and Thrombolytic Therapy for Ischemic Stroke: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition) Chest, June 1, 2008; 133(6_suppl): 630S - 669S. [Abstract] [Full Text] [PDF]

				B. M. Demaerschalk, B. J. Bobrow, and M. Paulsen Development of a Metropolitan Matrix of Primary Stroke Centers: The Phoenix Experience Stroke, April 1, 2008; 39(4): 1246 - 1253. [Abstract] [Full Text] [PDF]

				P. Khatri, R. A. Taylor, V. Palumbo, V. Rajajee, J. M. Katz, J. A. Chalela, A. Geers, J. Haymore, D. M. Kolansky, S. E. Kasner, et al. The safety and efficacy of thrombolysis for strokes after cardiac catheterization. J. Am. Coll. Cardiol., March 4, 2008; 51(9): 906 - 911. [Abstract] [Full Text] [PDF]

				T. R. Yip and B. M. Demaerschalk Estimated Cost Savings of Increased Use of Intravenous Tissue Plasminogen Activator for Acute Ischemic Stroke in Canada Stroke, June 1, 2007; 38(6): 1952 - 1955. [Abstract] [Full Text] [PDF]

				B. M. Demaerschalk and D. L. Durocher How Diagnosis-Related Group 559 Will Change the US Medicare Cost Reimbursement Ratio for Stroke Centers Stroke, April 1, 2007; 38(4): 1309 - 1312. [Abstract] [Full Text] [PDF]

				A. Kobayashi, M. Skowronska, T. Litwin, and A. Czlonkowska Lack of experience of intravenous thrombolysis for acute ischaemic stroke does not influence the proportion of patients treated Emerg. Med. J., February 1, 2007; 24(2): 96 - 99. [Abstract] [Full Text] [PDF]

				M. P. Goldberg New Approaches to Clinical Trials in Neuroprotection: Introduction Stroke, February 1, 2007; 38(2): 789 - 790. [Full Text] [PDF]

				L. Ehlers, G. Andersen, L. B. Clausen, M. Bech, and M. Kjolby Cost-Effectiveness of Intravenous Thrombolysis With Alteplase Within a 3-Hour Window After Acute Ischemic Stroke Stroke, January 1, 2007; 38(1): 85 - 89. [Abstract] [Full Text] [PDF]

				P. A. Scott, R. Silbergleit, B. M. Demaerschalk, and T. R. Yip Economic Benefit of Increasing Utilization of Intravenous Tissue Plasminogen Activator for Acute Ischemic Stroke in the United States Stroke, April 1, 2006; 37(4): 943 - 944. [Full Text] [PDF]